Technology areas: Biotechnology & Pharmaceuticals • Communications
18 pending office actions • 17 art units • 17 examiners • 0 of 18 (0%) have an AI response strategy ready • 69 patents granted in the last 365 days
NantWorks LLC has 18 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 17 distinct examiners and 17 distinct art units, showing that nearly every matter is being examined in a separate assignment.
LIU, GUOZHEN is the busiest identified examiner, with 2 pending matters. The limited cluster may support focused review, but the overall profile favors individualized claim strategy, examiner research, and deadline management rather than broad assumptions about prosecution treatment.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (6%) |
| §101 + other | 3 (17%) |
| §103 only | 8 (44%) |
| §112 only | 1 (6%) |
| Double-patenting only | 2 (11%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 2 (11%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIU, GUOZHEN | 2 | 48.1% | +26.0% |
| COBB, MICHAEL J | 1 | 76.9% | +35.5% |
| JOHNSON, CARLTON | 1 | 58.0% | +33.0% |
| LIU, GORDON G | 1 | 83.0% | +14.7% |
| SHAH, UTPAL D | 1 | 87.8% | +11.4% |
| NGUYEN, HAIDUNG D | 1 | 64.8% | +28.1% |
| FENSTERMACHER, JASON B | 1 | 47.3% | +37.4% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 51.8% | +27.5% |
| HUYNH, EMILY | 1 | 22.9% | +44.9% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.3% | +43.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18924777 | MARKER-BASED AUGMENTED REALITY AUTHORING TOOLS | LIU, GORDON G | — |
| 18920746 | OBJECT INGESTION AND RECOGNITION SYSTEMS AND METHODS | SHAH, UTPAL D | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17964015 | DISTRIBUTED RELATIONSHIP REASONING ENGINE FOR GENERATING ANALYTICS FOR HEMODYNAMIC INSTABILITY | HUYNH, EMILY | 41d |
| 18677737 | HEALTHCARE TRANSACTION VALIDATION VIA BLOCKCHAIN, SYSTEMS AND METHODS | FENSTERMACHER, JASON B | — |
| 18609750 | Oolitic Aragonite Beads and Methods Therefor | ATKINSON, JOSHUA ALEXANDER | — |
| 18769216 | Targeted IL-12 Treatments and Methods to Stimulate haNK and NK92mi Cells | DONOGHUE, BRITTNEY ERIN | — |
| 18474797 | Cancer Score for Assessment and Response Prediction from Biological Fluids | LIU, GUOZHEN | — |
| 18465868 | Cancer Score for Assessment and Response Prediction from Biological Fluids | LIU, GUOZHEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18719293 | GRANULAR COMPOSITION CONTAINING GRAPHENE AND A PARTICULATE MATERIAL, AND METHOD FOR PRODUCING IT | NGUYEN, HAIDUNG D | 31d overdue |
| 17964015 | DISTRIBUTED RELATIONSHIP REASONING ENGINE FOR GENERATING ANALYTICS FOR HEMODYNAMIC INSTABILITY | HUYNH, EMILY | 41d |
| 19543530 | LOCATION-BASED DIGITAL TOKEN MANAGEMENT SYSTEMS, METHODS, AND APPARATUS | COBB, MICHAEL J | — |
| 19023205 | ENHANCED ACCESS TO MEDIA, SYSTEMS AND METHODS | JOHNSON, CARLTON | — |
| 18924777 | MARKER-BASED AUGMENTED REALITY AUTHORING TOOLS | LIU, GORDON G | — |
| 18920746 | OBJECT INGESTION AND RECOGNITION SYSTEMS AND METHODS | SHAH, UTPAL D | — |
| 18677737 | HEALTHCARE TRANSACTION VALIDATION VIA BLOCKCHAIN, SYSTEMS AND METHODS | FENSTERMACHER, JASON B | — |
| 18609750 | Oolitic Aragonite Beads and Methods Therefor | ATKINSON, JOSHUA ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1686 | 2 |
| 2615 | 1 |
| 2436 | 1 |
| 2618 | 1 |
| 2668 | 1 |
| 1761 | 1 |
| 3698 | 1 |
| 1612 | 1 |
| 3683 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19543530 | LOCATION-BASED DIGITAL TOKEN MANAGEMENT SYSTEMS, METHODS, AND APPARATUS | COBB, MICHAEL J | 2615 | §112 | Final Rejection | — | Pending | Feb 18, 2026 |
| 19023205 | ENHANCED ACCESS TO MEDIA, SYSTEMS AND METHODS | JOHNSON, CARLTON | 2436 | §103 | Non-Final OA | — | Pending | Jan 15, 2025 |
| 18924777 | MARKER-BASED AUGMENTED REALITY AUTHORING TOOLS | LIU, GORDON G | 2618 | §103 | Final Rejection | — | Pending | Oct 23, 2024 |
| 18920746 | OBJECT INGESTION AND RECOGNITION SYSTEMS AND METHODS | SHAH, UTPAL D | 2668 | DP | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18719293 | GRANULAR COMPOSITION CONTAINING GRAPHENE AND A PARTICULATE MATERIAL, AND METHOD FOR PRODUCING IT | NGUYEN, HAIDUNG D | 1761 | §103 | Final Rejection | 31d overdue | Pending | Jun 13, 2024 |
| 18677737 | HEALTHCARE TRANSACTION VALIDATION VIA BLOCKCHAIN, SYSTEMS AND METHODS | FENSTERMACHER, JASON B | 3698 | §103§112 | Non-Final OA | — | Pending | May 29, 2024 |
| 18609750 | Oolitic Aragonite Beads and Methods Therefor | ATKINSON, JOSHUA ALEXANDER | 1612 | §101§102§103§112DP | Non-Final OA | — | Pending | Mar 19, 2024 |
| 17964015 | DISTRIBUTED RELATIONSHIP REASONING ENGINE FOR GENERATING ANALYTICS FOR HEMODYNAMIC INSTABILITY | HUYNH, EMILY | 3683 | §101 | Non-Final OA | 41d | Pending | Oct 11, 2022 |
| 17740040 | High-Throughput Identification of Patient-Specific Neoepitopes as Therapeutic Targets for Cancer Immunotherapies | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112DP | Non-Final OA | — | Pending | May 09, 2022 |
| 17236957 | VIRTUAL TELLER SYSTEMS AND METHODS | MAIDO, MAGGIE T | 2129 | §103 | Final Rejection | 19d | Pending | Apr 21, 2021 |
| 19454185 | haNK Cetuximab Combinations And Methods | GODDARD, LAURA B | 1642 | DP | Final Rejection | — | Pending | Jan 20, 2026 |
| 18972249 | Deep Learning Models For Region Of Interest Determination | ISMAIL, OMAR S | 2635 | §103 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18769216 | Targeted IL-12 Treatments and Methods to Stimulate haNK and NK92mi Cells | DONOGHUE, BRITTNEY ERIN | 1675 | §102§103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18671662 | Primary T-Cell Expansion | BELYAVSKYI, MICHAIL A | 1644 | §103 | Non-Final OA | — | Pending | May 22, 2024 |
| 18643905 | Monocarboxylic Acid Transporter 4 as a Biomarker for Hypoxia Driven Tumor Growth and Treatment | WOOLWINE, SAMUEL C | 1681 | §103 | Non-Final OA | — | Pending | Apr 23, 2024 |
| 16961026 | Fusion Protein Extensions | GAO, ASHLEY HARTMAN | 1678 | §103 | Final Rejection | 5d | Pending | Oct 15, 2020 |
| 18474797 | Cancer Score for Assessment and Response Prediction from Biological Fluids | LIU, GUOZHEN | 1686 | §101§103§112Other | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18465868 | Cancer Score for Assessment and Response Prediction from Biological Fluids | LIU, GUOZHEN | 1686 | §101§103§112 | Non-Final OA | — | Pending | Sep 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNantWorks LLC has 18 pending office actions as of October 2026, spread across 17 art units and 17 examiners.
Guozhen Liu has the most, with 2 of NantWorks LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
